Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
2D transition metal dichalcogenides (TMDs) have received widespread interest by virtue of their excellent electrical, optical, and electrochemical characteristics. Recent studies on TMDs have revealed their versatile utilization as electrocatalysts, supercapacitors, battery materials, and sensors, etc. In this study, MoS nanosheets are successfully assembled on the porous VS (P-VS ) scaffold to form a MoS /VS heterostructure. Their gas-sensing features, such as sensitivity and selectivity, are investigated by using a quartz crystal microbalance (QCM) technique. The QCM results and density functional theory (DFT) calculations reveal the impressive affinity of the MoS /VS heterostructure sensor toward ammonia with a higher adsorption uptake than the pristine MoS or P-VS sensor. Furthermore, the adsorption kinetics of the MoS /VS heterostructure sensor toward ammonia follow the pseudo-first-order kinetics model. The excellent sensing features of the MoS /VS heterostructure render it attractive for high-performance ammonia sensors in diverse applications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/smll.201901718 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer.
J Immunother Cancer
September 2025
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Background: Peltopepimut-S is a therapeutic vaccine, which induces specific expansion of both CD4+helper and CD8+cytotoxic T-cells against human papillomavirus type 16 (HPV16) E6/E7 oncoproteins.
Patients And Methods: In a randomized phase 2 trial, we evaluated the efficacy and safety of peltopepimut-S plus cemiplimab compared with cemiplimab alone as first-line or second-line therapy in recurrent/metastatic HPV16-positive head and neck cancer. The primary efficacy endpoint was the objective response rate (ORR) by an independent review (Response Evaluation Criteria in Solid Tumors version 1.
The survival analysis of stage III and IV inoperable lung large cell neuroendocrine carcinoma and the role of LIPI in immunological stratification.
Lung Cancer
August 2025
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou, China; Guangzhou Institute of Respiratory Health, Guangzhou, C
Background: Large cell neuroendocrine carcinoma (LCNEC) represents a rare and unique type of lung tumor with an unfavorable prognosis. It is essential to summarize the treatment modalities and prognosis for inoperable stage III and IV LCNEC, explore the role of frontline immunotherapy, and examine the stratification role of the Lung Immune Prognostic Index (LIPI) and its relationship with the tumor microenvironment (TME).
Methods: This study retrospectively analyzed 160 patients with inoperable lung LCNEC (L-LCNEC) admitted to three hospitals from December 2012 to November 2023.
Clinical and Genomic Features and Prognostic Biomarkers of Oligometastatic Nonsmall Cell Lung Cancer.
Clin Lung Cancer
July 2025
Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ. Electronic address:
Introduction: Treatment of metastatic disease is rapidly evolving with local therapies increasingly being used in patients with oligometastasis. Better personalization is needed to appropriate select patients for these interventions. We attempted to better understand clinical features and genomic features of oligometastatic nonsmall cell lung cancer (NSCLC).
View Article and Find Full Text PDFSafety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia.
Blood Adv
August 2025
Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah, United States.
Despite significant therapeutic advances in multiple myeloma (MM), outcomes in patients with plasma cell leukemia (PCL) remain dismal. We conducted a multicenter retrospective analysis of patients with PCL treated with the B-cell Maturation Antigen (BCMA)-directed Chimeric Antigen Receptor T-Cell (CAR-T) products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). We identified 34 patients, 19 patients received ide-cel and 15 received cilta-cel.
View Article and Find Full Text PDFEfficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study.
Hepatol Int
August 2025
Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, T
Background And Aims: Transarterial chemoembolization (TACE) combined with immunotherapy and targeted therapy provides a promising therapy for unresectable hepatocellular carcinoma (HCC). This study aimed to compare the efficacy and safety of TACE combined with atezolizumab and bevacizumab (TACE-Ate-Bev) or atezolizumab and bevacizumab alone (Ate-Bev) as first-line treatment for unresectable HCC.
Methods: This multicenter cohort study recruited patients with unresectable HCC who received TACE-Ate-Bev or Ate-Bev as first-line treatment between July 1, 2020 and December 31, 2023.